Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

HER-family ligands promote acquired resistance to trastuzumab in gastric cancer.

Sampera A, Sánchez-Martín FJ, Arpí O, Visa L, Iglesias M, Menéndez S, Gaye É, Dalmases A, Clavé S, Gelabert-Baldrich M, Poulsen TT, Kragh M, Bellosillo B, Albanell J, Rovira A, Montagut C.

Mol Cancer Ther. 2019 Sep 4. pii: molcanther.0455.2019. doi: 10.1158/1535-7163.MCT-19-0455. [Epub ahead of print]

PMID:
31484705
2.

Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer.

Carmona-Bayonas A, Jimenez-Fonseca P, Garrido M, Custodio A, Hernandez R, Lacalle A, Cano JM, Aguado G, Martínez de Castro E, Alvarez Manceñido F, Macias I, Visa L, Martín Richard M, Mangas M, Sánchez Cánovas M, Longo F, Iglesias Rey L, Martínez Lago N, Martín Carnicero A, Sánchez A, Azkárate A, Limón ML, Hernández Pérez C, Ramchandani A, Pimentel P, Cerdá P, Serrano R, Gil-Negrete A, Marín M, Hurtado A, Sánchez Bayona R, Gallego J.

Thromb Haemost. 2019 Aug 28. doi: 10.1055/s-0039-1694012. [Epub ahead of print]

PMID:
31461750
3.

Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry.

Viúdez A, Carmona-Bayonas A, Gallego J, Lacalle A, Hernández R, Cano JM, Macías I, Custodio A, Martínez de Castro E, Sánchez A, Iglesia L, Reguera P, Visa L, Azkarate A, Sánchez-Cánovas M, Mangas M, Limón ML, Martínez-Torrón A, Asensio E, Ramchandani A, Martín-Carnicero A, Hurtado A, Cerdà P, Garrido M, Sánchez-Bayonas R, Serrano R, Jiménez-Fonseca P; AGAMENON Study Group.

Clin Transl Oncol. 2019 Aug 5. doi: 10.1007/s12094-019-02183-y. [Epub ahead of print]

PMID:
31385226
4.

KRAS mutations in ctDNA: a promising new biomarker in advanced pancreatic cancer.

Montagut C, Vidal J, Visa L.

Ann Oncol. 2018 Dec 1;29(12):2280-2282. doi: 10.1093/annonc/mdy484. No abstract available.

PMID:
30423018
5.

Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker.

Martinez-Bosch N, Barranco LE, Orozco CA, Moreno M, Visa L, Iglesias M, Oldfield L, Neoptolemos JP, Greenhalf W, Earl J, Carrato A, Costello E, Navarro P.

Oncotarget. 2018 Aug 31;9(68):32984-32996. doi: 10.18632/oncotarget.26034. eCollection 2018 Aug 31.

6.

Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).

Maurel J, Sánchez-Cabús S, Laquente B, Gaba L, Visa L, Fabregat J, Povés I, Roselló S, Díaz-Beveridge R, Martín-Richard M, Rodriguez J, Sabater L, Conill C, Cambray M, Reig A, Ayuso JR, Valls C, Ferrández A, Bombí JA, Ginés A, García-Albéniz X, Fernández-Cruz L.

Cancer Chemother Pharmacol. 2018 Dec;82(6):935-943. doi: 10.1007/s00280-018-3682-9. Epub 2018 Sep 17.

PMID:
30225601
7.

Comparison of Perioperative Outcomes Between Laparoscopic and Open Approach for Pancreatoduodenectomy: The PADULAP Randomized Controlled Trial.

Poves I, Burdío F, Morató O, Iglesias M, Radosevic A, Ilzarbe L, Visa L, Grande L.

Ann Surg. 2018 Nov;268(5):731-739. doi: 10.1097/SLA.0000000000002893.

PMID:
30138162
8.

Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry.

Carmona-Bayonas A, Jiménez-Fonseca P, Echavarria I, Sánchez Cánovas M, Aguado G, Gallego J, Custodio A, Hernández R, Viudez A, Cano JM, Martínez de Castro E, Macías I, Martín Carnicero A, Garrido M, Mangas M, Álvarez Manceñido F, Visa L, Azkarate A, Ramchandani A, Fernández Montes A, Longo F, Sánchez A, Pimentel P, Limón ML, Arias D, Cacho Lavin D, Sánchez Bayona R, Cerdá P, García Alfonso P; AGAMENON Study Group.

Eur J Surg Oncol. 2018 Aug;44(8):1191-1198. doi: 10.1016/j.ejso.2018.03.019. Epub 2018 Mar 31.

PMID:
29685755
9.

Geriatric oncology in Spain: survey results and analysis of the current situation.

Gironés R, Morilla I, Guillen-Ponce C, Torregrosa MD, Paredero I, Bustamante E, Del Barco S, Soler G, Losada B, Visa L, Llabrés E, Fox B, Firvida JL, Blanco R, Antonio M, Aparisi F, Pi-Figueras M, Gonzalez-Flores E, Molina-Garrido MJ, Saldaña J; Spanish Working Group on Geriatric Oncology of the Spanish Society of Medical Oncology (SEOM).

Clin Transl Oncol. 2018 Aug;20(8):1087-1092. doi: 10.1007/s12094-017-1813-0. Epub 2017 Dec 11.

10.

Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis.

Visa L, Jiménez-Fonseca P, Martínez EA, Hernández R, Custodio A, Garrido M, Viudez A, Buxo E, Echavarria I, Cano JM, Macias I, Mangas M, de Castro EM, García T, Manceñido FÁ, Montes AF, Azkarate A, Longo F, Serrano AD, López C, Hurtado A, Cerdá P, Serrano R, Gil-Negrete A, Carnicero AM, Pimentel P, Ramchandani A, Carmona-Bayonas A; AGAMENON Study Group.

J Geriatr Oncol. 2018 May;9(3):254-264. doi: 10.1016/j.jgo.2017.11.008. Epub 2017 Dec 11.

PMID:
29242093
11.

Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry.

Jiménez Fonseca P, Carmona-Bayonas A, Hernández R, Custodio A, Cano JM, Lacalle A, Echavarria I, Macias I, Mangas M, Visa L, Buxo E, Álvarez Manceñido F, Viudez A, Pericay C, Azkarate A, Ramchandani A, López C, Martinez de Castro E, Fernández Montes A, Longo F, Sánchez Bayona R, Limón ML, Diaz-Serrano A, Martin Carnicero A, Arias D, Cerdà P, Rivera F, Vieitez JM, Sánchez Cánovas M, Garrido M, Gallego J.

Br J Cancer. 2017 Sep 5;117(6):775-782. doi: 10.1038/bjc.2017.245. Epub 2017 Aug 1.

12.

Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab.

Custodio A, Carmona-Bayonas A, Jiménez-Fonseca P, Sánchez ML, Viudez A, Hernández R, Cano JM, Echavarria I, Pericay C, Mangas M, Visa L, Buxo E, García T, Rodríguez Palomo A, Álvarez Manceñido F, Lacalle A, Macias I, Azkarate A, Ramchandani A, Fernández Montes A, López C, Longo F, Sánchez Bayona R, Limón ML, Díaz-Serrano A, Hurtado A, Madero R, Gómez C, Gallego J.

Br J Cancer. 2017 Jun 6;116(12):1526-1535. doi: 10.1038/bjc.2017.122. Epub 2017 May 2.

13.

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.

Vidal J, Muinelo L, Dalmases A, Jones F, Edelstein D, Iglesias M, Orrillo M, Abalo A, Rodríguez C, Brozos E, Vidal Y, Candamio S, Vázquez F, Ruiz J, Guix M, Visa L, Sikri V, Albanell J, Bellosillo B, López R, Montagut C.

Ann Oncol. 2017 Jun 1;28(6):1325-1332. doi: 10.1093/annonc/mdx125.

14.

Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry.

Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A, Sánchez Cánovas M, Hernández R, Pericay C, Echavarria I, Lacalle A, Visa L, Rodríguez Palomo A, Mangas M, Cano JM, Buxo E, Álvarez-Manceñido F, García T, Lorenzo JE, Ferrer-Cardona M, Viudez A, Azkarate A, Ramchandani A, Arias D, Longo F, López C, Sánchez Bayona R, Limón ML, Díaz-Serrano A, Fernández Montes A, Sala P, Cerdá P, Rivera F, Gallego J; AGAMENON study group.

Gastric Cancer. 2018 Jan;21(1):96-105. doi: 10.1007/s10120-017-0718-5. Epub 2017 Apr 9.

PMID:
28393278
15.

On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry.

Carmona-Bayonas A, Jiménez-Fonseca P, Lorenzo ML, Ramchandani A, Martínez EA, Custodio A, Garrido M, Echavarría I, Cano JM, Barreto JE, García TG, Manceñido FÁ, Lacalle A, Cardona MF, Mangas M, Visa L, Buxó E, Azkarate A, Díaz-Serrano A, Montes AF, Rivera F.

J Natl Compr Canc Netw. 2016 Nov;14(11):1379-1388.

PMID:
27799509
16.

Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer.

Jiménez-Fonseca P, Carmona-Bayonas A, Sánchez Lorenzo ML, Plazas JG, Custodio A, Hernández R, Garrido M, García T, Echavarría I, Cano JM, Rodríguez Palomo A, Mangas M, Macías Declara I, Ramchandani A, Visa L, Viudez A, Buxó E, Díaz-Serrano A, López C, Azkarate A, Longo F, Castañón E, Sánchez Bayona R, Pimentel P, Limón ML, Cerdá P, Álvarez Llosa R, Serrano R, Lobera MPF, Alsina M, Hurtado Nuño A, Gómez-Martin C.

Gastric Cancer. 2017 May;20(3):465-474. doi: 10.1007/s10120-016-0639-8. Epub 2016 Sep 6.

PMID:
27599830
17.

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.

Sánchez-Martín FJ, Bellosillo B, Gelabert-Baldrich M, Dalmases A, Cañadas I, Vidal J, Martinez A, Argilés G, Siravegna G, Arena S, Koefoed K, Visa L, Arpí O, Horak ID, Iglesias M, Stroh C, Kragh M, Rovira A, Albanell J, Tabernero J, Bardelli A, Montagut C.

Clin Cancer Res. 2016 Jul 1;22(13):3260-7. doi: 10.1158/1078-0432.CCR-15-2400. Epub 2016 Feb 17.

18.

Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.

Gomez-Martin C, Plaza JC, Pazo-Cid R, Salud A, Pons F, Fonseca P, Leon A, Alsina M, Visa L, Rivera F, Galan MC, Del Valle E, Vilardell F, Iglesias M, Fernandez S, Landolfi S, Cuatrecasas M, Mayorga M, Jose Paulés M, Sanz-Moncasi P, Montagut C, Garralda E, Rojo F, Hidalgo M, Lopez-Rios F.

J Clin Oncol. 2013 Dec 10;31(35):4445-52. doi: 10.1200/JCO.2013.48.9070. Epub 2013 Oct 14.

PMID:
24127447
19.

Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study.

Martin-Richard M, Gallego R, Pericay C, Garcia Foncillas J, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, Saigi E, Barnadas A, Garcia-Albeniz X, Maurel J.

Invest New Drugs. 2013 Dec;31(6):1573-9.

PMID:
24077981
20.

Serum 25-hydroxyvitamin D3 levels and vitamin D receptor variants in melanoma patients from the Mediterranean area of Barcelona.

Ogbah Z, Visa L, Badenas C, Ríos J, Puig-Butille JA, Bonifaci N, Guino E, Augé JM, Kolm I, Carrera C, Pujana MÁ, Malvehy J, Puig S.

BMC Med Genet. 2013 Feb 16;14:26. doi: 10.1186/1471-2350-14-26.

21.

Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.

Codony-Servat J, Marín-Aguilera M, Visa L, García-Albéniz X, Pineda E, Fernández PL, Filella X, Gascón P, Mellado B.

Prostate. 2013 Apr;73(5):512-21. doi: 10.1002/pros.22591. Epub 2012 Oct 4.

PMID:
23038213
22.

CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer.

Molina V, Visa L, Conill C, Navarro S, Escudero JM, Auge JM, Filella X, Lopez-Boado MA, Ferrer J, Fernandez-Cruz L, Molina R.

Tumour Biol. 2012 Jun;33(3):799-807. doi: 10.1007/s13277-011-0297-8. Epub 2011 Dec 29.

PMID:
22203495
23.

Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients.

Font C, Farrús B, Vidal L, Caralt TM, Visa L, Mellado B, Tàssies D, Monteagudo J, Reverter JC, Gascon P.

Ann Oncol. 2011 Sep;22(9):2101-6. doi: 10.1093/annonc/mdq720. Epub 2011 Feb 16.

PMID:
21325446
24.

Solid cancer, antiphospholipid antibodies, and venous thromboembolism.

Font C, Vidal L, Espinosa G, Tàssies D, Monteagudo J, Farrús B, Visa L, Cervera R, Gascon P, Reverter JC.

Autoimmun Rev. 2011 Feb;10(4):222-7. doi: 10.1016/j.autrev.2010.10.006. Epub 2010 Oct 16. Review.

PMID:
20955822
25.

[Response to metronomic chemotherapy in a metastatic adenoid cystic carcinoma of the parotid gland].

Visa L, Caballero M, Grau JJ.

Acta Otorrinolaringol Esp. 2010 Nov-Dec;61(6):452-4. doi: 10.1016/j.otorri.2009.10.008. Epub 2010 Feb 11. Spanish.

26.

Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients.

Martínez-Fernandez A, García-Albeniz X, Pineda E, Visa L, Gallego R, Codony-Servat J, Augé JM, Longarón R, Gascón P, Lacy A, Castells A, Maurel J.

Ann Surg Oncol. 2009 May;16(5):1412-20. doi: 10.1245/s10434-009-0405-9. Epub 2009 Mar 4.

PMID:
19259740
27.

Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway.

Mellado B, Codony J, Ribal MJ, Visa L, Gascón P.

Clin Transl Oncol. 2009 Jan;11(1):5-10. Review.

PMID:
19155198

Supplemental Content

Support Center